Skip to Main Content

Presentations

Development of a Phase III Allogeneic Cell Therapy Manufacturing Process – ARM Meeting on the Mesa 2024 Presentation

PDF · Published 2026-11-14 · 2 min read

Presentation

Jeff Zurawski, PhD, Associate Director, BioProcess Development, DiscGenics, Inc. Presented at the Alliance for Regenerative Medicine Meeting on the Mesa, 2024.

Jeff Zurawski, PhD, Associate Director of BioProcess Development at DiscGenics, presented this talk at the Alliance for Regenerative Medicine’s Meeting on the Mesa in 2024. It describes how DiscGenics moved its allogeneic cell therapy for lumbar disc degeneration, which is derived from intervertebral disc tissue, from a bench-scale Phase I/II process to a scalable Phase III and commercial process. That work included replacing proprietary and human-derived raw materials with defined formulations built on Cellastim S®, Optiferrin®, and Exbumin® recombinant proteins.

Why This Matters

Early-phase cell therapy processes often depend on proprietary supplements and human-derived components that are difficult to control at commercial scale. The presentation notes that the Phase I/II process used a proprietary cell culture supplement and cryopreservation media with human-derived components, and that the PMDA requires control of all raw materials. For Phase III, DiscGenics replaced both with defined, human-component-free formulations while maintaining comparability to the Phase I/II drug product.

  • A new growth medium adding 20 bioactive components, including albumin and transferrin, supported cell growth comparable to the proprietary Phase I/II supplement and removed human-derived components.
  • An excipient cryopreservation formulation of rHSA, DMSO, sodium hyaluronate, and buffer removed proprietary and human-derived components and incorporated sodium hyaluronate, which had previously been mixed at the clinic.
  • In post-thaw testing, an amino acid formulation maintained higher cell viability than the base formulation at 0, 6, and 12 hours.

Presentation Contents

  • Lumbar disc degeneration and clinical results for allogeneic disc progenitor cells on pain, disability, and disc volume
  • Phase III drug product specifications, adding potency assays tied to anti-inflammatory and extracellular matrix mechanisms of action
  • Moving from flask culture with viscous suspension media to stirred tank bioreactors, using a 250 mL small-scale model
  • Scale-up to 50 L pilot and 250 L commercial scale
  • Cell culture supplement and excipient cryopreservation formulation development
  • Small-scale model screening of donor lots against growth and potency acceptance criteria for Phase III

About This Resource

This presentation is the work of DiscGenics, Inc. InVitria supplied the Cellastim S® recombinant human serum albumin, Optiferrin® recombinant transferrin, and Exbumin® rHSA referenced in the cell culture supplement and cryopreservation sections, and is sharing the presentation here with that context.

More resources

Keep reading.

Talk to a Scientist

See how rHSA performs in your media.

Send us your cell line and formulation and we will help you design a side-by-side evaluation against your current albumin.